Wanbury

Which are the latest news on Wanbury?

Why is Wanbury Ltd falling/rising?

As of 05-Sep, Wanbury Ltd's stock price is rising to 246.50, reflecting a short-term gain after a decline, but it remains below key moving averages and faces reduced investor participation, indicating potential challenges ahead.

As of 05-Sep, Wanbury Ltd's stock price is rising, currently at 246.50, with a change of 2.5 (1.02%) upward. This increase comes after a trend reversal, as the stock has gained after four consecutive days of decline. Additionally, it has outperformed its sector by 2.07% today. <BR><BR>However, it is important to note that despite this rise, Wanbury Ltd is trading lower than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a longer-term downward trend. Furthermore, there has been a decline in investor participation, with delivery volume falling by 25.96% against the 5-day average. <BR><BR>Overall, while the stock is experiencing a short-term rise, the broader context shows challenges such as lower trading volumes and being below key moving averages, which could impact future performance.

Should I buy, sell or hold Wanbury Ltd?

Who are in the management team of Wanbury?

The management team of Wanbury includes N K Puri (Independent Director), K Chandran (Vice Chairman & Whole Time Director), Jitendra J Gandhi (Company Secretary & Compliance Officer), and several Independent Directors: Pallavi Shedge, Binod Chandra Maharana, Manisha Juvekar, Anupam Vaidya, and Pravin Dilip Pawar.

The management team of Wanbury includes the following individuals:<BR><BR>1. N K Puri - Independent Director<BR>2. K Chandran - Vice Chairman & Whole Time Director<BR>3. Jitendra J Gandhi - Company Secretary & Compliance Officer<BR>4. Pallavi Shedge - Independent Director<BR>5. Binod Chandra Maharana - Independent Director<BR>6. Manisha Juvekar - Independent Director<BR>7. Anupam Vaidya - Independent Director<BR>8. Pravin Dilip Pawar - Independent Director<BR><BR>If you have any more questions about Wanbury or its management, feel free to ask!

What does Wanbury do?

Wanbury Ltd is a micro-cap pharmaceutical company involved in research and related activities, with recent net sales of 166 Cr and a net profit of 3 Cr as of June 2026. The company has a market cap of INR 895 Cr and key financial metrics include a P/E ratio of 21.00 and a return on equity of 72.53%.

Overview:<BR>Wanbury Ltd is engaged in pharmaceutical and related activities, including research, and operates within the Pharmaceuticals & Biotechnology industry as a micro-cap company.<BR><BR>History:<BR>Incorporated in August 1988, Wanbury Ltd was formerly known as Pearl Organics Limited and changed its name in September 2004. The latest quarterly results reported net sales and profit for June 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 166 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 3 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 895 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 21.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 2.77 <BR>Return on Equity: 72.53% <BR>Price to Book: 15.12 <BR><BR>Contact Details:<BR>Address: BSEL Tech Park B-Wing 10th Flr, Sector 30 A Opp Vashi Rly Stat Navi Mumbai Maharashtra : 400703 <BR>Tel: 91-22-67942222 <BR>Email: shares@wanbury.com <BR>Website: http://www.wanbury.com

Who are the peers of the Wanbury?

Wanbury's peers include Themis Medicare, Bajaj Healthcare, Kopran, Bharat Parenter., Anlon Healthcare, Anuh Pharma, Amanta Healthcare, Zim Laboratories, and Remus Pharma. In terms of performance, Kopran leads with a 1-year return of 40.77%, while Wanbury has a return of -8.90%.

Peers: The peers of Wanbury are Themis Medicare, Bajaj Healthcare, Kopran, Bharat Parenter., Anlon Healthcare, Anuh Pharma, Amanta Healthcar, Zim Laboratories, and Remus Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Anlon Healthcare and Anuh Pharma, while Average management risk is found at Themis Medicare, Bajaj Healthcare, Kopran, Zim Laboratories, Remus Pharma, and Wanbury, and the rest. Growth is Excellent at Anlon Healthcare, while Average growth is seen at Wanbury, Themis Medicare, Bajaj Healthcare, Kopran, and the rest, and Below Average growth is noted at Bharat Parenter., Amanta Healthcar, Zim Laboratories, and Anuh Pharma. Capital Structure is Excellent at Anuh Pharma and Remus Pharma, Good at Kopran and Anlon Healthcare, while Below Average is found at Wanbury, Themis Medicare, Bajaj Healthcare, Bharat Parenter., Amanta Healthcar, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Kopran at 40.77%, while the lowest is Bajaj Healthcare at -21.10%. Wanbury's own 1-year return is -8.90%, which is better than Bajaj Healthcare but worse than Kopran. Additionally, Remus Pharma and Influx Health have a six-month return of 0.00%.

How big is Wanbury?

As of 31st August, Wanbury Ltd has a market capitalization of 895.00 Cr, with recent net sales of 629.82 Cr and a net profit of 42.99 Cr. Shareholder's funds are 59.27 Cr, and total assets are valued at 406.88 Cr as of March 2025.

As of 31st August, Wanbury Ltd has a market capitalization of 895.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Wanbury reported Net Sales of 629.82 Cr and a Net Profit of 42.99 Cr.<BR><BR>The latest reporting period for the balance sheet is March 2025, with Shareholder's Funds amounting to 59.27 Cr and Total Assets valued at 406.88 Cr.

When is the next results date for Wanbury Ltd?

The next results date for Wanbury Ltd is 11 August 2026.

The next results date for Wanbury Ltd is scheduled for 11 August 2026.

Is Wanbury technically bullish or bearish?

As of December 4, 2025, Wanbury's technical trend is mildly bearish, indicated by bearish momentum from the weekly MACD and KST, while daily moving averages and monthly indicators also reflect a cautious outlook.

As of 4 December 2025, the technical trend for Wanbury has changed from bearish to mildly bearish. The current technical stance is mildly bearish, driven by the weekly MACD and KST both indicating bearish momentum, while the monthly MACD and Bollinger Bands suggest a mildly bearish outlook. The daily moving averages also reflect a mildly bearish sentiment. The lack of clear signals from the RSI and no trends in Dow Theory and OBV further support the neutral stance in the short term. Overall, the indicators suggest a cautious approach as the stock remains below its previous highs.

How has been the historical performance of Wanbury?

Wanbury's historical performance shows growth in net sales and operating income, increasing from 499.65 Cr in Mar'23 to 599.51 Cr in Mar'25. However, profitability declined, with profit before tax dropping to 29.55 Cr in Mar'25, and total liabilities rose to 406.88 Cr, indicating mixed financial health.

Answer:<BR>The historical performance of Wanbury shows a fluctuating trend in key financial metrics over the years, with notable changes in net sales, profits, and overall financial health.<BR><BR>Breakdown:<BR>Wanbury's net sales increased from 499.65 Cr in Mar'23 to 599.51 Cr in Mar'25, reflecting a positive growth trajectory. Total operating income followed a similar pattern, rising to 599.51 Cr in Mar'25 from 499.65 Cr in Mar'23. However, the company faced challenges with profitability, as operating profit (PBDIT) rose to 79.80 Cr in Mar'25 from 24.08 Cr in Mar'23, but profit before tax dropped to 29.55 Cr in Mar'25 from 56.34 Cr in Mar'24. Profit after tax also decreased to 30.53 Cr in Mar'25 from 55.96 Cr in Mar'24. The company's total liabilities increased to 406.88 Cr in Mar'25 from 337.62 Cr in Mar'24, while total assets also rose to 406.88 Cr in Mar'25 from 337.62 Cr in Mar'24, indicating a growing balance sheet. Cash flow from operating activities improved to 26.00 Cr in Mar'25 from 4.00 Cr in Mar'24, although cash flow from investing activities showed a significant outflow of -51.00 Cr in Mar'25. Overall, Wanbury's financial performance reflects a mix of growth in sales and operating income, alongside challenges in profitability and increasing liabilities.

Is Wanbury overvalued or undervalued?

As of November 6, 2025, Wanbury is considered undervalued with an attractive valuation grade, supported by a PE ratio of 20.53, strong growth potential indicated by a PEG ratio of 0.41, and impressive operational efficiency metrics like a 27.43% ROCE and 51.53% ROE, especially when compared to its more expensive peers like Sun Pharma and Divi's Laboratories.

As of 6 November 2025, the valuation grade for Wanbury has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently assessed as undervalued. Key ratios supporting this assessment include a PE ratio of 20.53, an EV to EBITDA of 11.90, and a PEG ratio of 0.41, which suggests strong growth potential relative to its price.<BR><BR>In comparison to its peers, Wanbury's valuation stands out favorably against Sun Pharma Industries, which is considered expensive with a PE ratio of 35.02, and Divi's Laboratories, which is categorized as very expensive with a PE ratio of 79.09. Additionally, while Wanbury's ROCE is an impressive 27.43% and ROE is a remarkable 51.53%, these figures further highlight its operational efficiency and profitability relative to its peers. Despite recent underperformance against the Sensex in the year-to-date period, Wanbury's long-term returns over three and five years significantly outperform the index, reinforcing its attractive valuation.

Are Wanbury latest results good or bad?

Wanbury's latest results show strong annual growth, with a 118.3% increase in Profit Before Tax and a 23.90% rise in net sales. However, recent quarter-on-quarter declines in net sales and profit raise concerns, leading to a cautious outlook.

Wanbury's latest results present a mixed picture. On one hand, the company has shown significant growth in key financial metrics compared to previous quarters. For the quarter ending June 2025, Wanbury reported a Profit Before Tax (PBT) of Rs 13.26 crore, which is an impressive increase of 118.3% compared to the average PBT from the prior four quarters. Similarly, the Profit After Tax (PAT) rose by 76.7% to Rs 13.49 crore.<BR><BR>Additionally, Wanbury's net sales for the latest six months reached Rs 335.18 crore, reflecting a year-on-year growth of 23.90%. The cash and cash equivalents also improved, reaching Rs 12.83 crore, indicating better short-term liquidity.<BR><BR>However, there are concerns regarding the quarter-on-quarter performance. Wanbury experienced a decline in net sales by 5.13% and a significant drop in consolidated net profit by 33.42% compared to the previous quarter. These downward trends in key metrics suggest challenges in maintaining momentum.<BR><BR>Despite the overall positive annual growth, the recent quarter's performance and the 'Sell' call issued by MarketsMOJO indicate that there may be caution warranted regarding the stock. Therefore, while there are strong annual results, the recent quarterly performance raises some red flags.

Who are the top shareholders of the Wanbury?

The top shareholders of Wanbury include Expert Chemicals (India) Pvt Ltd with 30.53%, individual investors with 41.78%, and public shareholder Suresh Bhatia at 3.58%. Additionally, 7 Foreign Institutional Investors hold 1.55%, while pledged promoter holdings are at 76.74%.

The top shareholders of Wanbury include a mix of promoters and individual investors. The largest promoter is Expert Chemicals (India) Pvt Ltd, holding 30.53% of the shares. Additionally, individual investors collectively hold 41.78% of the company. The highest public shareholder is Suresh Bhatia, who owns 3.58%. There are also 7 Foreign Institutional Investors (FIIs) with a combined holding of 1.55%, while mutual funds currently do not hold any shares in the company. The pledged promoter holdings stand at 76.7355%.

Has Wanbury declared dividend?

Yes, Wanbury Ltd has declared a 10% dividend, amounting to 1 per share, with an ex-date of July 29, 2010. However, the dividend yield is 0%, indicating that returns have primarily come from price appreciation rather than dividend income.

Wanbury Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: Jul-29-2010<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was 5.38%, the dividend return was 0%, resulting in a total return of 5.38%.<BR><BR>In the 1-year period, the price return was 103.38%, the dividend return was 0%, resulting in a total return of 103.38%.<BR><BR>In the 2-year period, the price return was 420.47%, the dividend return was 0%, resulting in a total return of 420.47%.<BR><BR>In the 3-year period, the price return was 337.36%, the dividend return was 0%, resulting in a total return of 337.36%.<BR><BR>In the 4-year period, the price return was 179.36%, the dividend return was 0%, resulting in a total return of 179.36%.<BR><BR>In the 5-year period, the price return was 1328.57%, the dividend return was 0%, resulting in a total return of 1328.57%.<BR><BR>Overall, while Wanbury Ltd has declared a dividend, the dividend yield remains at 0%, indicating that the returns have primarily come from price appreciation rather than dividend income. The total returns over various periods show significant growth, particularly over the longer term.